Trial Profile

A phase I study of AT9283 given as a 24 hour infusion on days 1 and 8 every three weeks in patients with advanced incurable malignancy.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 08 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AT 9283 (Primary)
Indications Non-Hodgkin's lymphoma; Solid tumours
Focus Adverse reactions; Pharmacokinetics

Most Recent Events

08 Feb 2017 Results of population model of AT9283 developed from the data of phase I trials of AT9283 (NCT00443976, NCT00522990, NCT00985868 and NCT01431664) published in the British Journal of Clinical Pharmacology.
12 Nov 2010 Results from this trial will be presented at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics according to a Astex Therapeutics media release.
26 Nov 2009 Planned end date changed from 1 Aug 2009 to 24 Nov 2009 as reported by National Cancer Institute of Canada record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com